Leukemia Therapy – A Look Into the Future
Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
Clinical Interchange™: Improving Outcomes and Overcoming Barriers to Equitable Care in African American Patients With Multiple Myeloma
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Gastrointestinal Malignancies from Paris
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
4th annual Precision Medicine Symposium: An Illustrated Tumor Board
Optimizing Pain Management for Breast Cancer Surgery Patients in the Age of the Opioid Epidemic
Pembrolizumab Combo Yields Benefits in pMMR/dMMR Advanced Endometrial CancerMarch 28th 2023
Pembrolizumab plus chemotherapy followed by maintenance pembrolizumab reduced the risk of death or disease progression in patients with mismatch repair proficient or deficient advanced endometrial cancer.
Post-Surgical Radiation Omission did not Raise Breast Cancer Distant RecurrenceMarch 28th 2023
Overall survival after 10 years appears to be comparable regardless of whether patients 65 years or older received irradiation following surgery for low-risk, hormone receptor–positive breast cancer.
Durvalumab Combo Appears Tolerable in Gynecologic Cancers
Durvalumab plus tremelimumab and hypofractionated radiotherapy yields observable clinical benefits in patients with gynecologic cancers, according to an expert from The University of Texas MD Anderson Cancer Center.
Questionnaires Are Comparable in Assessing Lymphedema in Endometrial CancerMarch 27th 2023
The lower extremity lymphedema screening questionnaire and gynecological cancer lymphedema questionnaire appear to demonstrate comparable utility in assessing lymphedema in patients with advanced endometrial cancer.
Dose Modification of Maintenance Niraparib May Not Impact PFS in Ovarian CancerMarch 27th 2023
A post hoc analysis demonstrated that dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival among patients with newly diagnosed, advanced ovarian cancer.
Addition of Dual Checkpoint Blockade Inhibition Improves PFS in Ovarian Cancer
Durvalumab plus tremelimumab in combination with neoadjuvant chemotherapy did not yield any major adverse effects in patients with newly diagnosed advanced ovarian cancer in the phase 2 KGOG3046 trial.
Adding HIPEC to Cytoreductive Surgery Does Not Impact HRQOL in Ovarian CancerMarch 25th 2023
Vadim Gushchin, MD, says that treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of negatively impacting health-related quality of life in ovarian cancer.
Zolbetuximab Combo Should be Considered New SOC in Gastric Cancer SubtypeMarch 23rd 2023
Efficacy and safety findings from the phase 3 GLOW trial assessing zolbetuximab and CAPOX in CLDN18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma were consistent with the phase 3 SPOTLIGHT trial, according to an expert from Weill Cornell Medical College